Nurix Therapeutics (NRIX) Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Revenue data on file, last reported at $6.3 million in Q1 2026.

• Revenue for Q1 2026 came in at $6.3 million, down 66.12% year-over-year; the trailing twelve-month figure through Feb 2026 was $42.7 million (down 24.27% YoY), and the FY2025 annual result was $84.0 million, up 53.95% from the prior year.
• Revenue slipped to $6.3 million in Q1 2026 per NRIX's latest filing, from $13.6 million in the prior quarter.
• Over five years, Revenue peaked at $30.7 million in Q2 2023 and troughed at $6.3 million in Q1 2026.
• A 5-year average of $13.6 million and a median of $12.7 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2026: Revenue soared 168.33% in 2023, then plunged 66.12% in 2026.
• A 5-year view of Revenue shows it stood at $6.8 million in 2022, then jumped by 123.49% to $15.2 million in 2023, then declined by 12.37% to $13.3 million in 2024, then climbed by 2.21% to $13.6 million in 2025, then slumped by 53.95% to $6.3 million in 2026.
• Business Quant data shows NRIX's Revenue at $6.3 million in Q1 2026, $13.6 million in Q4 2025, and $7.9 million in Q3 2025.